Targeted therapies have recently changed the approach to advanced melanoma. RAF inhibitors represent the emerging standard of care for metastatic BRAF mutated melanomas. Cutaneous reactions are the most common side effects during vemurafenib treatment, and affect the quality of life. The aim of this study was to provide some practical advices to manage the drug related cutaneous reactions.

Dermatological approach to vemurafenib skin toxicity: a single centre experience

Fava, Paolo;Marra, Elena;Astrua, Chiara;Brizio, Matteo;Cavaliere, Giovanni;Quaglino, Pietro;Fierro, Maria T;Savoia, Paola
2016

Abstract

Targeted therapies have recently changed the approach to advanced melanoma. RAF inhibitors represent the emerging standard of care for metastatic BRAF mutated melanomas. Cutaneous reactions are the most common side effects during vemurafenib treatment, and affect the quality of life. The aim of this study was to provide some practical advices to manage the drug related cutaneous reactions.
151
1
25
31
Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Dose-Response Relationship, Drug; Exanthema; Female; Humans; Indoles; Keratinocytes; Keratoacanthoma; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Mutation; Photosensitivity Disorders; Proto-Oncogene Proteins B-raf; Risk Factors; Skin Neoplasms; Sulfonamides; Vemurafenib; Warts
Fava, Paolo; Marra, Elena; Astrua, Chiara; Brizio, Matteo; Cavaliere, Giovanni; Quaglino, Pietro; Fierro, Maria T; Savoia, Paola
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1815350
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact